Hussein Al-Mossawi
Company: Immunocore Ltd
Job title: Vice president of Immunology
Bio:
Dr. Hussein Al-Mossawi, Vice President of Immunology Research at Immunocore, leads the development of T cell receptor-based immunotherapies for autoimmune and inflammatory diseases. A clinician scientist with 15+ years’ experience in rheumatology and immunology drug development, he previously held research and clinical development roles at AstraZeneca and UCB. Hussein earned his medical degree and doctorate from the University of Oxford, leading a translational immunology research group focused on pathological immune responses in inflammatory diseases. He is a fellow and lecturer in pathology and immunology at St Edmund Hall, University of Oxford and an honorary visiting professor at the department of Rheumatology in Leeds University.
Seminars:
Chair’s Opening Remarks 8:00 am
day: Day One
Pharma Icebreaker: Partnering & Innovation in Autoimmunity: Targets, Modalities & Next Generation Biologics 8:10 am
Exploring pharma’s evolving strategy across known targets, new modalities, and combination therapies to shape future partnering discussions Evaluating autoimmune cell therapy and next generation biologics to understand their capacity to drive future investments Uncovering key competitive differentiators prioritised in search and evaluation processes to drive deal-making and partnership decisionsRead more
day: Day One
Investor Icebreaker: When Being Selective, What Will Investors Choose? 11:30 am
Understanding venture focus across asset-centred investments and early-stage innovation to guide strategic investment discussions Discussing preferences for broad platforms or highly specific assets to understand asset maximization from a venture perspective Identifying exciting modalities, underestimated modalities and targets gaining traction in the global market to anticipate the next wave of autoimmune innovationRead more
day: Day One
Analyzing In Vivo Approaches, Delivery & Safety to Uncover their Future Potential 3:10 pm
Exploring the therapeutic potential of in vivo approaches, including in vivo and B-cell depletion to anticipate a future developments Assessing if the rules that govern cancer therapies are applicable to autoimmunity to effectively evaluate knockout strategies with lentiviral vectors or opportunities for redosing with mRNA Debating safety versus efficacy in the context of LNP and…Read more
day: Day One